On April 10, 2020 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, reported the appointment of Sir Harpal Kumar as President of GRAIL Europe (Press release, Grail, APR 10, 2020, View Source [SID1234556247]). In this new role, Sir Harpal will be responsible for leading GRAIL’s entry and growth in Europe.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am delighted to welcome Harpal to the GRAIL team. He is a passionate advocate for better outcomes in cancer, with a widely recognized appreciation of the challenges health systems face in battling the increasing burden of this disease," said Hans Bishop, Chief Executive Officer at GRAIL. "With Harpal’s leadership, we can build partnerships that will bring the benefits of early cancer detection to patients and providers in Europe.’’
"I’m thrilled to be joining GRAIL and to have the opportunity to transform cancer care through early detection," said Sir Harpal. "I look forward to leading the company’s partnerships with European medical and healthcare services and the broader innovation community to support our goal of decreasing the burden of cancer."
Sir Harpal joins GRAIL from Johnson & Johnson where he most recently served as Senior Vice President and Head of Innovation EMEA. There, he oversaw a portfolio of co-investments and collaborations across the region to grow Johnson & Johnson’s networks within the EMEA innovation community. Before joining Johnson & Johnson Innovation, Sir Harpal spent 15 years with Cancer Research UK, and served as the organization’s Chief Executive Officer from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK). Before CRUK, he worked with McKinsey & Co, The Papworth Trust, and Nexan Group. Sir Harpal received a Masters in Chemical Engineering from the University of Cambridge, and an MBA as a Baker Scholar from Harvard Business School. He has been awarded Honorary Doctorates from the Universities of Manchester, Newcastle, and Glasgow, and the Institute of Cancer Research, and he is a Fellow of The Academy of Medical Sciences. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.